Table 1 Baseline demographic and clinical characteristics of the pooled study populations
Pooled population | |||
|---|---|---|---|
Characteristic | Placebo (n = 209) | Esomeprazole 20 mg (n = 201) | Esomeprazole 40 mg (n = 194) |
Male/female gender, percentage | 27.3:72.7 | 21.4:78.6 | 24.2: 75.8 |
Age in years, mean (standard deviation) | 57.1 (13.4) | 54.4 (11.9) | 55.7 (13.6) |
Type of chronic condition, percentage | |||
Rheumatoid arthritis | 24.4 | 18.4 | 20.6 |
Osteoarthritis | 43.1 | 45.3 | 42.8 |
Other chronic condition | 32.5 | 36.3 | 36.6 |
Time since first diagnosis of chronic condition in years, median | 9 | 7 | 9 |
Helicobacter pylori status (histology), percentagea | |||
Negative | 95.7 | 93.0 | 95.9 |
Positive | 3.3 | 6.5 | 3.1 |
Unknown | 1.0 | 0.5 | 1.0 |
NSAID type, percentage | |||
Non-selective | 64.1 | 65.7 | 67.0 |
Selective COX-2 inhibitor | 35.9 | 34.3 | 33.0 |
Study drug in acute study, percentage | |||
Placebo | 24.4 | 29.3 | 32.5 |
Esomeprazole 20 mg | 43.1 | 32.8 | 36.1 |
Esomeprazole 40 mg | 32.5 | 37.8 | 31.4 |